オプションチェーンは、Invivydの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Invivydの市場センチメントを評価します。.

Invivyd (NASDAQ:IVVD) 株価情報, オプションチェーン

INVIVYD INC

Invivyd

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Invivyd Inc

News

9F Inc Receives Nasdaq Letter Regarding Late Filing of Form 20-F

Buybacks

REAX

Real Brokerage Board Authorizes New Share Repurchase Program For Up To Lesser Of $150M In Value, Or 35M In Shares

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) has outperformed the market over the past 5 years by 276.89% on an annualized basis producing an average annual return of 290.74%. Currently, Quest Diagnostics has a market capitalization of $19.32 billion. 
Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $1,019,647.06 today based on a price of $173.07 for DGX at the time of writing.
<h3>Quest Diagnostics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748637015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 22.08% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 19.73% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 13.64% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed up 9.67% at $0.48</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 6.06% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 5.77% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 4.14% at $1.79</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 3.54% at $7.42</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 3.25% at $0.28</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 50.00% at $0.0002</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 22.81% at $1.32</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 20.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 11.29% at $0.60</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 8.49% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 7.15% at $0.43</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 5.88% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 5.36% at $0.83</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 3.27% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 3.08% at $1.27</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 3.07% at $4.00</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

CLSH

CRBP

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CVSI

FFNTF

ITHUF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

NWVCF

OILFF

RMHB

SNDL

SOLCF

TCNNF

TGIFF

TLRY

ZDPY

Marijuana Stock Movers For May 30, 2025

Offerings

Haoxi Health Technology Files For Mixed Shelf Of Up To $80M

A gauge tracking the so-called &#8220;magnificent seven&#8221; — which includes Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) — surged 15% in May.
The rally coincided with an especially solid month for U.S. equities. The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), surged more than 6% for the month. That&#8217;s its strongest month since November 2023.
But beneath the surface <a href="https://www.benzinga.com/general/education/25/05/45675595/apple-eyes-worst-month-vs-sp-500-since-2018-but-history-says-buy-the-dip-now#:~:text=Apple%2520underperformed%2520S%2526P%2520500%2520by,expert%2520insights%2520for%252060%2525%2520off.">is Apple's rare underperformance.</a>
Six out of the magnificent seven tech giants logged monthly gains. The iPhone maker, however, lagged its peers and delivered its weakest relative performance against the S&amp;P 500 Index since 2018.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="535" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30154913/image-426-1024x535.png" alt="" class="wp-image-933762" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30154913/image-426-1024x535.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30154913/image-426-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30154913/image-426-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30154913/image-426-1536x803.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30154913/image-426-2048x1070.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
In contrast, Nvidia posted a staggering 24% monthly jump — its best performance since May 2024 — after delivering <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45668727/nvidia-stock-is-surging-thursday-whats-fueling-the-move">better-than-expected quarterly earnings.</a>
Despite facing export restrictions on its chips to China, Nvidia's revenue resilience confirmed that artificial <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45675006/nvidia-stock-has-significant-upside-as-ai-godfather-jensen-huang-delivers-another-robust-quarter">intelligence demand remains healthy.</a> Overall revenue reached $44.1 billion, up 69% from a year ago.
"Countries around the world are recognizing AI as essential infrastructure — just like electricity and the internet — and Nvidia stands at the center of this profound transformation," CEO Jensen Huang said.
While Wall Street paints a positive picture, Main Street tells a different story, as pessimism among U.S. consumers runs high.
The U.S. economy contracted by 0.2% <a href="https://www.benzinga.com/government/regulations/25/05/45669445/us-economy-contracts-by-02-in-q1-labor-market-shows-signs-of-cracks-as-jobless-claims-surge">in the first quarter</a>, a slight upward revision from the initial -0.3% estimate, yet a stark reversal from the 2.4% growth rate seen in late 2024. Inflation, as measured by the <a href="https://www.benzinga.com/cannabis/25/05/45693219/feds-favorite-inflation-gauge-slows-but-trumps-china-accusation-flips-market-mood">Personal Consumption Expenditures price index</a>, cooled to 2.1% in April — its lowest pace in six months — from 2.3% in March.
But the public doesn&#8217;t seem to trust the disinflation narrative.
According to the University of Michigan's May survey, Americans expect inflation to run at 6.6% over the next year, <a href="https://www.benzinga.com/markets/economic-data/25/05/45697983/consumer-sentiment-stuck-at-3-year-lows-as-inflation-fears-hit-44-year-high">the highest level since 1981</a>. That figure reflects the widest gap ever recorded between perceived and actual inflation. Meanwhile, overall sentiment remains near three-year lows.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="535" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30155117/image-427-1024x535.png" alt="" class="wp-image-933763" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30155117/image-427-1024x535.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30155117/image-427-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30155117/image-427-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30155117/image-427-1536x803.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30155117/image-427-2048x1070.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
In a notable development on the trade front, the U.S. Court of International Trade struck down significant portions of President Donald Trump's newly proposed tariff actions.
While the move sparked brief investor optimism, analysts caution the Trump administration retains various legal avenues to <a href="https://www.benzinga.com/government/regulations/25/05/45672421/tariffs-blocked-by-court-but-goldman-sachs-says-trump-could-reimpose-them-within-days">reintroduce similar trade barriers.</a>
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/05/45703175/netflix-stock-could-climb-another-25-thanks-to-second-half-content-bonanza-says-bank-of-america">Netflix Stock Could Climb Another 25% Thanks To Second-Half &#8216;Content Bonanza,&#8217; Says Bank Of America </a></li>
</ul>
Image: Shutterstock

Tech

AAPL

AMZN

GOOGL

MSFT

NVDA

TSLA

Magnificent Seven Drive Wall Street's Rally, Nvidia Notches Best Month In A Year: This Week In Markets

Meta Platforms Shareholders Reject Dual Class Capital Structure Proposal

General

Eversource Energy Enters Equity Distribution Agreement With Multiple Manager; To Issue And Sell Shares Up To $1.2B

On May 29, 2025, D-Wave Quantum Inc. (the "Company") received proceeds in the aggregate amount of approximately $80.5 million in connection with the exercise of approximately 7.0 million warrants to purchase shares of the Company's common stock with an exercise price of $11.50 per warrant. These warrants were assumed by the Company in conjunction with the August 5, 2022 merger with DPCM Capital, Inc.

QBTS

D-Wave Quantum Receives ~$80.5M from Exercise Of 7M Warrants At $11.50 Each, Originating From 2022 Merger With DPCM Capital

Modiv Industrial Files For Mixed Shelf Of Up to $250M

CMDB

Costamare Bulkers Files For Mixed Shelf Of Up To $200M

On May 27, 2025, Brendon Fischer, the Interim Chief Financial Officer of Sow Good Inc. (the "Company"), informed the Company of his decision to resign, effective June 6, 2025. Mr. Fischer will assist the Company to ensure the successful transition of his responsibilities prior to his departure. His resignation is not the result of any disagreement with the Company regarding its operations, accounting or other policies or practices.

Management

SOWG

Sow Good Announces Brendon Fischer To Resign As Interim CFO, Effective June 6, 2025

RVPH

Reviva Pharmaceuticals  Enters Into At Market Issuance Sales Agreement; To Offer Up To $50M In Common Stock

CACI

CACI International Awarded Nearly $638M In New Contracts Within Intelligence Community To Support National Security Efforts

Financing

Humana Enters Into $5B Unsecured Revolving Credit Agreement; Agreement Permits Up To $1B Of Incremental Commitments; New Agreement Replaces Existing $2.1B Credit Agreement

Color Star Technology Co Louis Luo Resigned From His Position As Ceo; Samantha Huang Appointed As Ceo

SIEB

Siebert Financial Files For Mixed Shelf Of Up To $100M

<ul>
<li>The Generation Essentials Group and Black Spade Acquisition II Co Expect to Close the Business Combination on June 3, 2025.</li>
<li>TGE's Class A Ordinary Shares and Warrants are Expected to Be Listed on the New York Stock Exchange and NYSE American under Ticker Symbols "TGE" and "TGEWS", Respectively, Shortly After the Closing of the Business Combination, on a Date to be Announced.</li>
</ul>
The Generation Essentials Group ("TGE") and Black Spade Acquisition II Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSII#NASDAQ">BSII</a>) ("Black Spade II") today announced that their previously announced business combination (the "Business Combination") was approved at an extraordinary general meeting of Black Spade II's shareholders on May 30, 2025.
Complete official results of the vote will be included in a current report on Form 8-K to be filed by Black Spade II with the U.S. Securities and Exchange Commission.
The Business Combination is expected to close on June 3, 2025. Upon such closing, TGE will remain as the combined company, and its Class A ordinary shares and warrants are expected to be listed on the New York Stock Exchange and NYSE American under the ticker symbols "TGE" and "TGEWS", respectively, shortly thereafter, on a date to be announced.

BSII

Generation Essentials Group And Black Spade Acquisition II Co Set To Close Business Combination On June 3, 2025; TGE Shares To Trade On NYSE Under Ticker Symbol "TGE" Following Closing

DIST

Distoken Acquisition Corp Enters Business Combination Agreement With Youlife Group

Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(0.25) by 376 percent. This is a 58.67 percent decrease over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $1.06 million which missed the analyst consensus estimate of $1.48 million by 28.61 percent. This is a 36.85 percent decrease over sales of $1.68 million the same period last year.

Earnings

Earnings Misses

PSTV

Plus Therapeutics Q1 EPS $(1.19) Misses $(0.25) Estimate, Sales $1.06M Miss $1.48M Estimate

Press Releases

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Health Care

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

Comments

Invivyd

Invivyd (IVVD) オプション

Invivyd (NASDAQ:IVVD) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル